Inventiva SA at JPMorgan Healthcare Conference Transcript
Welcome, ladies and gentlemen. Welcome to the last day of the JPMorgan Healthcare Conference and today's presentation from Inventiva. It's my pleasure to introduce Andrew Obenshain, CEO of Inventiva. We'll first do the presentation. After that, there's, time for some questions, so feel free to save those to the end, and I'll leave it to Andrew to take us through.
Thank you very much and thank you for having us to this conference and thank you for ordering up some beautiful weather this week. I'm glad to see there's a sellout crowd of hundreds of people in the audience, for those people online. A lot of interest in Inventiva today.
So, again, I'm Andrew Obenshain. I'm the CEO of Inventiva. Today I'm going to talk about the company and our lead asset, Lanifibranor, which has the potential to be best in disease, for MASH as an oral therapy. This is my disclaimer. This contains this presentation contains forward-looking statements. I will not read the whole thing.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
